Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 4/20 | 0.39 |
| ▸ | TDP2 | O95551 | 2/20 | 0.37 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 4/20 | 0.35 |
| ▸ | BRAF | P15056 | 4/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | TLR4 | O00206 | 1/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.33 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24007635 | 0.80 | MPO (0.36) | TDP2PLATPSMB8PSMB9PSMB5 | |
| SCHEMBL25745860 | 0.77 | KDM4E (0.38) | TLR9TLR8TLR7BRD4PLAT | |
| SCHEMBL24816299 | 0.77 | CACNA1H (0.34) | TLR9TLR8TLR7TDP2PLAT | |
| SCHEMBL12506496 | 0.76 | HSD11B1 (0.37) | C5AR1PSMB8PSMB9PSMB5 | |
| SCHEMBL24007638 | 0.74 | P2RX7 (0.32) | TDP2PLATPSMB8PSMB9PSMB5 | |
| SCHEMBL25746175 | 0.73 | MPO (0.35) | — | |
| SCHEMBL11793035 | 0.72 | PLAT (0.37) | PLATPSMB8PSMB9PSMB5CRACR2A | |
| SCHEMBL26605749 | 0.71 | HSD11B1 (0.35) | PSMB8PSMB9PSMB5 | |
| SCHEMBL16081467 | 0.71 | SMN1; SMN2 (0.41) | BRD4 | |
| SCHEMBL23269807 | 0.71 | MPO (0.34) | C5AR1PLATPSMB8PSMB9PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | TLR9 3739/4885TLR8 3827/4885TLR7 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.